Your browser doesn't support javascript.
loading
A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer.
Geynisman, Daniel M; Maranchie, Jodi K; Ball, Mark W; Bratslavsky, Gennady; Singer, Eric A.
Affiliation
  • Geynisman DM; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address: daniel.geynisman@fccc.edu.
  • Maranchie JK; Department of Urology, University of Pittsburgh, Pittsburgh, PA.
  • Ball MW; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Bratslavsky G; Department of Urology, SUNY Upstate Medical University, Syracuse, NY.
  • Singer EA; Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
Urol Oncol ; 39(9): 548-560, 2021 09.
Article in En | MEDLINE | ID: mdl-34092483
ABSTRACT
The diagnosis, evaluation and management of patients with renal cell carcinoma has transformed in the 21st century. Utilizing biological discoveries and technological advances, the field has moved from blunt surgical and largely ineffective medical treatments, to nuanced and fine-tuned approaches based on biology, extent of disease and patient preferences. In this review we will summarize the last 25 years of progress in kidney cancer.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Transitional Cell / Biomedical Research / Kidney Neoplasms Limits: Humans Language: En Journal: Urol Oncol Journal subject: NEOPLASIAS / UROLOGIA Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Transitional Cell / Biomedical Research / Kidney Neoplasms Limits: Humans Language: En Journal: Urol Oncol Journal subject: NEOPLASIAS / UROLOGIA Year: 2021 Document type: Article